Index -
P/E -
EPS (ttm) -1.62
Insider Own 2.41%
Shs Outstand 365.24M
Perf Week -2.91%
Market Cap 3.16B
Forward P/E 2.11
EPS next Y 4.10
Insider Trans -0.07%
Shs Float 356.59M
Perf Month -7.68%
Income -592.00M
PEG -
EPS next Q 0.69
Inst Own 79.13%
Short Float 6.31%
Perf Quarter 6.13%
Sales 8.76B
P/S 0.36
EPS this Y 12.75%
Inst Trans 18.44%
Short Ratio 7.95
Perf Half Y 17.19%
Book/sh -2.80
P/B -
EPS next Y 4.68%
ROA -2.23%
Short Interest 22.50M
Perf Year 13.20%
Cash/sh 2.63
P/C 3.29
EPS next 5Y 2.60%
ROE -
52W Range 5.57 - 11.46
Perf YTD 7.98%
Dividend Est. -
P/FCF 4.09
EPS past 5Y 32.76%
ROI -2.81%
52W High -24.43%
Beta 0.90
Dividend TTM -
Quick Ratio 0.94
Sales past 5Y 1.03%
Gross Margin 58.48%
52W Low 55.47%
ATR (14) 0.49
Dividend Ex-Date Aug 30, 2010
Current Ratio 1.30
EPS Y/Y TTM -160.23%
Oper. Margin 18.34%
RSI (14) 37.50
Volatility 6.98% 5.46%
Employees 20270
Debt/Eq -
Sales Y/Y TTM 7.79%
Profit Margin -6.76%
Recom 2.83
Target Price 10.33
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 90.57%
Payout -
Rel Volume 0.76
Prev Close 8.74
Sales Surprise 4.99%
EPS Surprise -4.77%
Sales Q/Q 9.80%
Earnings Feb 22 BMO
Avg Volume 2.83M
Price 8.66
SMA20 -10.12%
SMA50 -5.83%
SMA200 4.50%
Trades
Volume 2,161,931
Change -0.92%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-20-23 Upgrade
Jefferies
Hold → Buy
$9 → $16
Jun-16-23 Downgrade
TD Cowen
Outperform → Market Perform
Jul-29-22 Downgrade
Truist
Buy → Hold
Jul-29-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$12 → $5
Jul-28-22 Downgrade
JP Morgan
Overweight → Neutral
Jun-13-22 Resumed
JP Morgan
Overweight
$12
Mar-24-21 Downgrade
BofA Securities
Neutral → Underperform
$27
Feb-17-21 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$26 → $42
Jan-22-21 Downgrade
Piper Sandler
Overweight → Neutral
$25 → $30
Sep-17-20 Upgrade
BofA Securities
Underperform → Neutral
$19
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$64 → $50
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$50 → $64
Jun-17-20 Reiterated
H.C. Wainwright
Buy
$50 → $64
Apr-24-20 Initiated
Citigroup
Buy
$30
Apr-02-20 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Jan-29-20 Downgrade
Wolfe Research
Outperform → Peer Perform
Jan-22-20 Upgrade
Wells Fargo
Underweight → Equal Weight
$32
Dec-12-19 Upgrade
JP Morgan
Neutral → Overweight
$32 → $38
Dec-02-19 Initiated
Goldman
Neutral
Oct-25-19 Initiated
Cowen
Outperform
$35
Show Previous Ratings
Apr-11-24 04:22PM
01:03PM
12:40PM
12:10PM
11:17AM
11:03AM
Loading…
11:03AM
08:00AM
Apr-08-24 05:33PM
01:27PM
Apr-05-24 06:15PM
Apr-03-24 12:05PM
09:50AM
08:00AM
Apr-02-24 08:00AM
Mar-28-24 02:19PM
05:23AM
Loading…
05:23AM
Mar-15-24 09:50AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Mar-01-24 08:00AM
Feb-27-24 03:27AM
Feb-23-24 12:25PM
11:53AM
Feb-22-24 11:30AM
10:03AM
09:30AM
08:25AM
07:33AM
07:33AM
(Associated Press Finance)
07:00AM
12:10PM
Loading…
Feb-21-24 12:10PM
07:26AM
(Associated Press Finance)
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-12-24 08:00AM
Feb-08-24 10:59AM
Feb-07-24 12:00PM
Feb-01-24 04:10PM
08:00AM
Jan-31-24 04:00PM
Jan-30-24 05:54PM
08:00AM
Jan-18-24 04:50PM
08:00AM
Jan-08-24 11:15AM
Dec-22-23 10:23AM
Dec-21-23 07:00AM
Dec-18-23 09:40AM
08:00AM
Dec-13-23 07:43AM
Dec-11-23 09:55AM
Dec-05-23 08:00AM
Nov-30-23 09:40AM
Nov-24-23 09:55AM
Nov-13-23 09:55AM
Nov-10-23 12:42PM
08:00AM
Nov-08-23 08:00AM
Nov-03-23 02:03PM
12:47PM
Nov-02-23 04:13PM
11:00AM
09:41AM
(Associated Press Finance)
08:34AM
07:00AM
Nov-01-23 12:22PM
10:43AM
10:40AM
09:30AM
07:07AM
(Associated Press Finance)
Oct-31-23 02:58AM
Oct-30-23 04:35PM
Oct-26-23 10:02AM
10:02AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 05:20PM
Oct-17-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-04-23 08:00AM
Sep-29-23 10:15AM
Sep-26-23 08:54AM
Sep-21-23 11:16AM
08:00AM
Sep-20-23 11:25AM
10:50AM
Sep-19-23 04:32PM
02:37PM
01:46PM
11:47AM
Sep-18-23 05:45PM
Sep-15-23 08:25AM
Sep-12-23 08:00AM
Sep-11-23 04:04PM
09:04AM
08:00AM
Sep-06-23 06:16PM
Aug-25-23 09:40AM
Aug-23-23 03:49AM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Carson Seana EVP, General Counsel Mar 04 '24 Sale 9.80 6,313 61,867 499,905 Mar 04 04:16 PM Carson Seana EVP, General Counsel Dec 05 '23 Sale 7.38 220 1,624 382,925 Dec 05 04:35 PM Carson Seana EVP, General Counsel Nov 06 '23 Sale 7.61 43 327 384,836 Nov 06 05:06 PM Carson Seana EVP, General Counsel Sep 06 '23 Sale 8.28 6,685 55,352 385,213 Sep 06 04:33 PM
Index -
P/E -
EPS (ttm) -0.53
Insider Own 15.69%
Shs Outstand 74.72M
Perf Week 1.61%
Market Cap 94.15M
Forward P/E -
EPS next Y -0.58
Insider Trans 5.20%
Shs Float 63.00M
Perf Month -19.23%
Income -32.48M
PEG -
EPS next Q -0.14
Inst Own 13.30%
Short Float 0.36%
Perf Quarter -5.97%
Sales 8.23M
P/S 11.44
EPS this Y 0.89%
Inst Trans -7.09%
Short Ratio 0.62
Perf Half Y 40.83%
Book/sh -0.25
P/B -
EPS next Y -10.28%
ROA -76.15%
Short Interest 0.22M
Perf Year 15.60%
Cash/sh 0.39
P/C 3.26
EPS next 5Y -
ROE -1310.02%
52W Range 0.65 - 2.12
Perf YTD 7.69%
Dividend Est. -
P/FCF -
EPS past 5Y 27.88%
ROI -121.55%
52W High -40.57%
Beta 2.38
Dividend TTM -
Quick Ratio 4.42
Sales past 5Y 1621.13%
Gross Margin 94.87%
52W Low 93.82%
ATR (14) 0.15
Dividend Ex-Date -
Current Ratio 4.42
EPS Y/Y TTM 3.80%
Oper. Margin -302.02%
RSI (14) 42.22
Volatility 8.37% 11.09%
Employees 30
Debt/Eq -
Sales Y/Y TTM 519.89%
Profit Margin -394.91%
Recom 1.00
Target Price 5.40
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 51.62%
Payout -
Rel Volume 0.89
Prev Close 1.15
Sales Surprise 43.12%
EPS Surprise 9.40%
Sales Q/Q 1822.73%
Earnings Mar 12 AMC
Avg Volume 362.85K
Price 1.26
SMA20 -13.82%
SMA50 -13.38%
SMA200 10.48%
Trades
Volume 323,002
Change 9.57%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-15-21 Resumed
Wedbush
Outperform
$19 → $9
Jul-29-21 Initiated
H.C. Wainwright
Buy
$10
May-13-20 Initiated
ROTH Capital
Buy
$8
Aug-09-19 Downgrade
Needham
Buy → Hold
Nov-05-18 Downgrade
Stifel
Buy → Hold
Nov-05-18 Downgrade
JP Morgan
Overweight → Underweight
Nov-05-18 Downgrade
Cowen
Outperform → Market Perform
Mar-06-18 Reiterated
Needham
Buy
$18 → $22
May-25-17 Initiated
JMP Securities
Mkt Outperform
$21
Feb-24-17 Initiated
JP Morgan
Overweight
$19
Nov-10-16 Reiterated
Needham
Buy
$16 → $24
Oct-24-16 Reiterated
Stifel
Buy
$13 → $23
Show Previous Ratings
Apr-16-24 07:05AM
Apr-02-24 07:05AM
Mar-18-24 07:05AM
Mar-13-24 08:30AM
06:38AM
(Thomson Reuters StreetEvents)
05:35PM
Loading…
Mar-12-24 05:35PM
04:05PM
Mar-06-24 02:25PM
Feb-29-24 07:05AM
Feb-25-24 01:37PM
Feb-07-24 08:00AM
Dec-14-23 07:05AM
Nov-14-23 09:11AM
Nov-13-23 04:05PM
Nov-08-23 07:05AM
04:20PM
Loading…
Nov-07-23 04:20PM
Nov-03-23 12:00PM
Nov-02-23 07:05AM
Nov-01-23 07:05AM
Oct-31-23 07:05AM
Oct-26-23 12:24AM
Oct-16-23 07:05AM
Oct-04-23 09:00AM
Oct-03-23 04:35PM
Sep-19-23 07:05AM
Aug-14-23 04:05PM
Aug-02-23 04:30PM
Aug-01-23 07:05AM
Jul-31-23 07:05AM
Jul-20-23 07:05AM
04:05PM
Loading…
Jul-11-23 04:05PM
Jul-10-23 07:05AM
Jun-29-23 09:50AM
Jun-01-23 07:05AM
May-11-23 08:25AM
07:05AM
May-09-23 04:30PM
May-02-23 07:05AM
Apr-27-23 07:05AM
Apr-18-23 07:05AM
Apr-12-23 07:05AM
Apr-09-23 09:42AM
Apr-05-23 07:05AM
Mar-11-23 03:14AM
Mar-09-23 06:35PM
04:05PM
Feb-23-23 07:05AM
Feb-21-23 07:05AM
Feb-07-23 07:05AM
Feb-06-23 07:30AM
Feb-02-23 01:18PM
07:05AM
Dec-22-22 09:52AM
05:05AM
Nov-22-22 07:05AM
Nov-11-22 05:26AM
Nov-10-22 01:24PM
07:05AM
Nov-09-22 09:05AM
07:15AM
07:05AM
Nov-08-22 04:05PM
Nov-02-22 07:05AM
Oct-31-22 08:52AM
Oct-17-22 11:27AM
Oct-04-22 07:05AM
Sep-27-22 07:05AM
Aug-25-22 07:05AM
Aug-11-22 06:21AM
Aug-09-22 08:35AM
07:05AM
Aug-08-22 04:30PM
08:05AM
Aug-03-22 07:05AM
Jul-27-22 07:05AM
Jul-26-22 07:05AM
Jul-09-22 08:25AM
Jul-07-22 07:05AM
Jun-14-22 07:05AM
Jun-08-22 07:05AM
May-11-22 05:25PM
04:05PM
May-05-22 07:05AM
Apr-29-22 07:05AM
Apr-11-22 07:44AM
Apr-06-22 07:05AM
Mar-28-22 06:59AM
Mar-15-22 06:38PM
Mar-10-22 05:25PM
04:05PM
Mar-03-22 07:05AM
Mar-01-22 07:05AM
Feb-28-22 08:25AM
Feb-25-22 07:05AM
Feb-14-22 04:05PM
Feb-11-22 05:42AM
Feb-02-22 07:05AM
Dec-21-21 07:05AM
Dec-13-21 04:05PM
05:17AM
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chong Ngai Hang Victor CHIEF MEDICAL OFFICER Mar 20 '24 Buy 1.60 30,000 48,000 30,000 Mar 20 04:30 PM WHITMORE BRADFORD T 10% Owner Feb 07 '24 Buy 1.35 444,444 599,999 4,495,034 Feb 09 01:00 PM LASEZKAY GEORGE M CEO Jan 19 '24 Sale 1.27 18,000 22,860 466,577 Jan 19 06:26 PM Deignan Charles A. Chief Financial Officer Jan 19 '24 Sale 1.28 12,900 16,512 384,662 Jan 19 06:25 PM WHITMORE BRADFORD T 10% Owner Nov 01 '23 Buy 0.74 64,366 47,901 4,050,590 Nov 01 04:24 PM WHITMORE BRADFORD T 10% Owner Oct 31 '23 Buy 0.73 70,812 51,537 3,986,224 Nov 01 04:24 PM WHITMORE BRADFORD T 10% Owner Oct 30 '23 Buy 0.69 600 411 3,915,412 Nov 01 04:24 PM Hutson Nancy J Director Oct 03 '23 Buy 0.86 10,000 8,600 93,000 Oct 04 05:06 PM Thorp Clay Director Sep 25 '23 Buy 0.86 10,000 8,600 40,522 Sep 25 04:34 PM Humphries William D. Director Sep 22 '23 Option Exercise 0.40 22,727 9,091 51,040 Sep 22 04:35 PM Deignan Charles A. Chief Financial Officer Sep 13 '23 Option Exercise 0.40 34,090 13,636 397,562 Sep 13 06:55 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite